Last reviewed · How we verify
Reversal of moderate neuromuscular blockade
Reversal of moderate neuromuscular blockade is a Small molecule drug developed by Pontificia Universidade Catolica de Sao Paulo. It is currently FDA-approved.
At a glance
| Generic name | Reversal of moderate neuromuscular blockade |
|---|---|
| Sponsor | Pontificia Universidade Catolica de Sao Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low Pressure Pneumoperitoneum and Postoperative Ileus (NA)
- Bleeding in Laparoscopic Liver Surgery (NA)
- Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) (PHASE4)
- Role of Curarization During Anesthesia for Laparoscopic Hysterectomy (PHASE2)
- Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade (PHASE1, PHASE2)
- The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach (PHASE4)
- Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium (PHASE4)
- The Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reversal of moderate neuromuscular blockade CI brief — competitive landscape report
- Reversal of moderate neuromuscular blockade updates RSS · CI watch RSS
- Pontificia Universidade Catolica de Sao Paulo portfolio CI
Frequently asked questions about Reversal of moderate neuromuscular blockade
What is Reversal of moderate neuromuscular blockade?
Reversal of moderate neuromuscular blockade is a Small molecule drug developed by Pontificia Universidade Catolica de Sao Paulo.
Who makes Reversal of moderate neuromuscular blockade?
Reversal of moderate neuromuscular blockade is developed and marketed by Pontificia Universidade Catolica de Sao Paulo (see full Pontificia Universidade Catolica de Sao Paulo pipeline at /company/pontificia-universidade-catolica-de-sao-paulo).
What development phase is Reversal of moderate neuromuscular blockade in?
Reversal of moderate neuromuscular blockade is FDA-approved (marketed).